Recent Investment Analysts’ Ratings Updates for Centene (CNC)

Several brokerages have updated their recommendations and price targets on shares of Centene (NYSE: CNC) in the last few weeks:

• 11/2/2026 – Centene had its “buy” rating reaffirmed by Truist Financial. They now have a $82.00 price target on the stock, up from $80.00.
• 10/31/2026 – Centene was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/30/2026 – Centene had its price target raised by Wells Fargo & Company from $69.00 to $75.00. They now have an “equal weight” rating on the stock.
• 10/29/2026 – Centene had its “hold” rating reaffirmed by Jefferies Financial Group. They now have a $69.00 price target on the stock.
• 10/29/2026 – Centene had its price target raised by JPMorgan Chase & Co. from $67.00 to $75.00. They now have a “neutral” rating on the stock.
• 10/28/2026 – Centene was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 10/28/2026 – Centene was given a new $79.00 price target by Raymond James Financial.
• 10/28/2026 – Centene was given a new $71.00 price target by Morgan Stanley. They now have an “equal weight” rating on the stock.
• 10/28/2026 – Centene was given a new $72.00 price target by Mizuho.
• 10/28/2026 – Centene had its “buy” rating reaffirmed by Bank of America. They now have a $82.00 price target on the stock, up from $80.00.
• 10/28/2026 – Centene had its price target raised by UBS Group from $70.00 to $78.00. They now have a “neutral” rating on the stock.
• 10/28/2026 – Centene had its price target raised by Barclays from $80.00 to $82.00. They now have an “overweight” rating on the stock.
• 10/28/2026 – Centene had its price target raised by Cantor Fitzgerald from $75.00 to $79.00. They now have an “overweight” rating on the stock.
• 10/28/2026 – Centene had its price target raised by Robert W. Baird from $66.00 to $71.00. They now have a “neutral” rating on the stock.
• 10/9/2026 – Centene had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 10/8/2026 – Centene was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 10/5/2026 – Centene was downgraded by Zacks Research from “strong-buy” to “hold”.
• 9/11/2026 – Centene had its “buy” rating reaffirmed by HC Wainwright.
• 9/11/2026 – Centene had its “overweight” rating reaffirmed by Cantor Fitzgerald.

Centene Price Performance

Shares of NYSE CNC traded up $6.81 during midday trading on Wednesday, hitting $74.29. The company had a trading volume of 5,440,751 shares, compared to its average volume of 5,617,300. The business has a 50-day simple moving average of $66.16 and a two-hundred day simple moving average of $55.47. The firm has a market capitalization of $36.78 billion, a price-to-earnings ratio of 25.44, a price-to-earnings-growth ratio of 0.39 and a beta of 1.07. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.69. Centene Corporation has a twelve month low of $31.63 and a twelve month high of $74.34.

Centene (NYSE:CNC) last posted its earnings results on Tuesday, October 27th. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.48. The firm had revenue of $50.65 billion during the quarter, compared to the consensus estimate of $47.12 billion. Centene had a net margin of 0.72% and a return on equity of 12.15%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period last year, the firm posted $0.50 EPS. Equities research analysts anticipate that Centene Corporation will post 5.26 earnings per share for the current year.

Insiders Place Their Bets

In other Centene news, General Counsel Christopher Koster sold 56,500 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $66.90, for a total value of $3,779,850.00. Following the transaction, the general counsel directly owned 248,854 shares in the company, valued at approximately $16,648,332.60. This represents a 18.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.37% of the company’s stock.

Centene Corporation is a diversified healthcare enterprise that provides government-sponsored and commercial health insurance programs and related healthcare services. The company’s offerings are primarily focused on Medicaid, Medicare, and health insurance marketplace plans, with an emphasis on serving individuals and families who may have limited access to traditional healthcare coverage.

Centene operates Medicaid health plans through state-based contracts and offers Medicare Advantage, Medicare prescription drug, and Medicare Supplement products through its Wellcare brand.